ArticleFrontiers in immunology2026
Integrative single-cell and bulk transcriptomics uncovers a lipid metabolism-related lncRNA signature alongside the ELFN1-AS1/LYPLA1 axis driving osteosarcoma progression.
Article in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteosarcoma is the most prevalent primary malignant bone tumor in adolescents, featuring prominent intratumoral heterogeneity, early pulmonary metastasis and stagnant survival improvement for metastatic/chemoresistant patients. Altered lipid metabolism represents as a core adaptive hallmark of malignancy, whereas the prognostic implication and molecular regulatory functions of lipid metabolism-related long non-coding RNAs (LMRLs) remain poorly elucidated in osteosarcoma. Methods: Single-cell RNA-seq data from GSE152048 and bulk transcriptomic and clinical data from TARGET-OS were integrated. Lipid metabolic activity, malignant cell-state transitions, and intercellular communication were evaluated using AUCell, Monocle, and CellChat, respectively. Lipid metabolism-related genes were identified by integrating single-cell differential expression analysis with WGCNA. A prognostic lncRNA signature was constructed using Pearson correlation, Cox regression, and LASSO analyses. Immune infiltration, tumor mutational burden, immune checkpoint expression, and drug sensitivity were further assessed. scTenifoldKnk-based virtual knockout screening was performed to predict downstream target genes of ELFN1-AS1, followed by comprehensive Results: Single-cell analysis revealed marked lipid-metabolic heterogeneity across osteosarcoma cell populations, with dynamic remodeling along malignant cell-state transitions and enhanced communication between high-lipid-metabolism osteosarcoma cells and stromal or vascular compartments. By integrating single-cell and bulk transcriptomic evidence, 22 lipid metabolism-related candidate genes were identified, from which a five-LMRL signature comprising AL133410.1, AL596247.1, ELFN1-AS1, IL10RB-DT, and NECTIN3-AS1 was developed. This signature effectively stratified patients into prognostically distinct risk groups and remained an independent predictor of overall survival. Exploratory computational analyses indicated risk subgroups exhibited divergent immune landscapes, mutational profiles and predicted drug responsiveness. Virtual knockout screening prioritized LYPLA1 as the key downstream effector of ELFN1-AS1. Among the signature lncRNAs, ELFN1-AS1 was prominently upregulated in osteosarcoma tissues and cells and was associated with poor prognosis. Mechanistically, ELFN1-AS1 drives osteosarcoma progression by triggering LYPLA1-dependent lipid accumulation-associated phenotype. Pharmacological blockade of Conclusion: This study establishes an LMRL-based for osteosarcoma prognostic stratification that reflects immune, genomic and therapeutic heterogeneity. Combining virtual knockout screening and experimental validation, we characterize the oncogenic ELFN1-AS1/LYPLA1 regulatory cascade as a potential biomarker and therapeutic target for precision management of osteosarcoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.